Carbon transformation company Twelve and biotechnology company LanzaTech partnered to transform CO2 emissions into polypropylene, a key polymer used for medical devices including syringes and IV bags, as well as for large-scale applications in automotive, furniture, textiles and other everyday products.
lululemon Athletica inc. signed a multi-year collaboration with sustainable materials leader Genomatica to bring renewably-sourced, bio-based materials into lululemon’s products. This represents lululemon’s first-ever equity investment in a sustainable materials company and Genomatica’s largest partnership within the retail industry. Together, the two companies will create a lower-impact, plant-based nylon to replace conventional nylon, which is the largest volume of synthetic material currently used to make lululemon products.
Clariant, a focused, sustainable and innovative specialty chemical company, and India Glycols Limited (IGL), a leading company in the manufacturing of green technology-based chemicals, successfully created their 51-49% joint venture for renewable ethylene oxide (EO) derivatives after receiving all necessary regulatory approvals. The joint venture will operate under the name Clariant IGL Specialty Chemicals Private Limited.
French biotech company Global Bioenergies announced the upcoming launch of its “LAST®” longwear cosmetics brand in June 2021. Eighteen products will comprise the world’s first range of longwear, transfer-resistant and waterproof eye make-up to use natural ingredients. This groundbreaking performance is based on the renewable isododecane produced by the Company as the main ingredient of its formulations. Products have been designed with over 90% natural ingredients and packaging to minimise their environmental footprint.
Denver, Colorado
DMC Biotechnologies and Conagen Inc. have entered into a manufacturing agreement for the commercial production of DMC’s first product, L-alanine. L-alanine is a naturally occurring amino acid used widely in homecare products, human nutrition, and pharmaceutical applications. DMC’s fermentation technology enables L-alanine to be produced with attractive economics as part of a regional supply chain with increased reliability and greater sustainability.
“Simplification of the European regulatory framework could also go a long way toward accelerating and promoting the circular bioeconomy surge.“ Nicolas Sordet, founder and CEO of AFYREN, talks to Il Bioeconomista. Founded in 2012 and headquartered in France, AFYREN collected more than €70 million funding in 2019, which allows the company to grow from a pilot stage to industrial-scale production.
Interview by Mario Bonaccorso
Australian biochemicals company Circa Group AS has successfully completed a private placement of 575 Norwegian Kroner (NOK) – approximately €56 million – in a transaction led by Pareto Securities and Sparebank 1 Markets in Oslo, at a post-money market valuation of approximately NOK 2 billion (approximately €194 million). The company (ticker code: CIRCA) shares started trading on Euronext Growth Oslo at 09:00 CET yesterday (2 March 2021).
“It is in everyone’s interests for life-sustaining chemicals to be manufactured both safely and reliably. We would argue that it is also extremely important that those chemicals be as sustainable as possible, so that future generations will have a habitable plant to use them on.” Jason Camp, CTO at Circa Group, talks to Il Bioeconomista. The Australia-based company is converting waste biomass into advanced biochemical materials.
Interview by Mario Bonaccorso
“We are hoping that the next US government will take climate change seriously and will take material steps to improve its leadership on the global stage.”
To say it – in this exclusive interview with Il Bioeconomista – is Matt Lipscomb, CEO of DMC Bio, the US company which is producing bio-based chemicals using fermentation.
Interview by Mario Bonaccorso
Amyris, Inc., a leading synthetic biotechnology company in Clean Health and Beauty markets and IDRI (Infectious Disease Research Institute) signed a binding term sheet for a planned COVID-19 RNA (ribonucleic acid) vaccine technology program. The program combines IDRI’s expertise in combating infectious diseases with Amyris’ fermentation platform technology, with the goal to create semi-synthetic squalene-based adjuvants at scale.
IL BIOECONOMISTA 